Author

Serhii Shevnia

Observed name: S. Shevnia

OpenAlex ID: A5113882435

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

2019 · Luis Paz-Ares, Mikhail Dvorkin, et al. · The Lancet · 2,281

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

2020 · Jonathan W Goldman, Mikhail Dvorkin, et al. · The Lancet Oncology · 688

Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)

2021 · Dmytro Trukhin, Elena Poddubskaya, et al. · BioDrugs · 27

Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC).

2023 · Erika P. Hamilton, Jee Hyun Kim, et al. · Journal of Clinical Oncology · 24

A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer

2020 · Martin Reck, Alexander Luft, et al. · Lung Cancer · 24

A phase III study comparing SB8, a proposed bevacizumab biosimilar, and reference bevacizumab in patients with metastatic or recurrent non-squamous NSCLC

2019 · M. Reck, A. Luft, et al. · Annals of Oncology · 4

Bevacizumab biosimilar and reference bevacizumab in subjects with stage IIIB/IV no squamous non-small cell lung cancer (NSCLC) (STELLA study): Results for the primary endpoint in a confirmatory, double-blind, randomized, controlled study.

2020 · Susana Millan, Dmytro Trukhin, et al. · Journal of Clinical Oncology · 1

610P Systemic therapy for bone marrow carcinomatosis in metastatic breast cancer: Is there a chance when there seems to be none?

2025 · Y. Haborets, S. Shevnia · Annals of Oncology

Bevacizumab biosimilar (MB02) and reference bevacizumab in patients with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC) (STELLA study): Multiple Imputation analysis.

2021 · Dmytro Trukhin, Elena Poddubskaya, et al. · Journal of Clinical Oncology

Works count: 9

Citation count: 3,046

H-index: 5

I10-index: 5